← Leaderboards
Richard P Junghans
It Bio, Llc
$3,250,862
Attributed
$3,250,862
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,250,862 · 1
By mechanism
R44$3,250,862 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAntigensAntibodiesAreaBaseB-LymphocytesBostonAntisense TechnologyCcr5 GeneCd28 GeneCd4 AntigensCd4 Positive T LymphocytesCd8b1 GeneCd8-Positive T-LymphocytesCell PhysiologyCellsCancer CellCheckpoint ReceptorsChimeric Antigen ReceptorChimeric Antigen Receptor T CellsChronicChronic InfectionClinical TrialsCollaborations
Grant awards (4)
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model$1,000,000
R44 · FY2024 · AI · contact PI
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model$1,000,000
R44 · FY2023 · AI · contact PI
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model$1,000,000
R44 · FY2022 · AI · contact PI
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model$250,862
R44 · FY2020 · AI · contact PI